This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, T. E. Articles by Lidgard, G. P. Search for Related Content PubMed PubMed Citation Articles by Miller, T. E. Articles by Lidgard, G. P.

Detection of Nuclear Matrix Proteins in Serum from Cancer Patients

Matritech, Inc., Cambridge, Massachusetts 02138

Morphological characteristics of the cell nucleus have long been used by pathologists in the clinical diagnosis of cancer. The nuclear matrix of the cell, the structure that serves to organize the chromatin within the nucleus, is known to reflect these morphological characteristics with regard to cell and cancer type. Monoclonal antibodies were developed to extracted nuclear matrix proteins. These antibodies were used in two-site immunometric assays to detect soluble nuclear matrix proteins in the supernatants of two dying cell lines and 15 tumor tissues. Furthermore, nuclear matrix proteins were detected at elevated levels in the sera of cancer patients compared with normal patient sera. In one assay, 63.2% of cancer sera read above 95% of normal sera, and in another assay, 73.7% of cancer sera read above 95% of the normal sera. With the development of monoclonal antibodies with greater cancer specificity, the detection of circulating nuclear matrix proteins may become an important clinical tool in the diagnosis and monitoring of cancer.

¹ To whom requests for reprints should be addressed, at Matritech, Inc., 763 Concord Avenue, Cambridge, MA 02138.

Received 8/ 5/91. Accepted 11/ 1/91.

This article has been cited by other articles:

				E. S. Leman, R. E. Schoen, A. Magheli, L. J. Sokoll, D. W. Chan, and R. H. Getzenberg Evaluation of Colon Cancer-Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1349 - 1354. [Abstract] [Full Text] [PDF]

				E. S. Leman, R. E. Schoen, J. L. Weissfeld, G. W. Cannon, L. J. Sokoll, D. W. Chan, and R. H. Getzenberg Initial Analyses of Colon Cancer-Specific Antigen (CCSA)-3 and CCSA-4 as Colorectal Cancer-Associated Serum Markers Cancer Res., June 15, 2007; 67(12): 5600 - 5605. [Abstract] [Full Text] [PDF]

				H. B. Grossman, E. Messing, M. Soloway, K. Tomera, G. Katz, Y. Berger, and Y. Shen Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay JAMA, February 16, 2005; 293(7): 810 - 816. [Abstract] [Full Text] [PDF]

				D. S. Coffey Nuclear Matrix Proteins as Proteomic Markers of Preneoplastic and Cancer Lesions : Commentary re: G. Brunagel et al., Nuclear Matrix Protein Alterations Associated with Colon Cancer Metastasis to the Liver. Clin. Cancer Res., 8: 3039-3045, 2002. Clin. Cancer Res., October 1, 2002; 8(10): 3031 - 3033. [Full Text] [PDF]

				G. Brunagel, R. E. Schoen, A. J. Bauer, B. N. Vietmeier, and R. H. Getzenberg Nuclear Matrix Protein Alterations Associated with Colon Cancer Metastasis to the Liver Clin. Cancer Res., October 1, 2002; 8(10): 3039 - 3045. [Abstract] [Full Text] [PDF]

				G. Brunagel, B. N. Vietmeier, A. J. Bauer, R. E. Schoen, and R. H. Getzenberg Identification of Nuclear Matrix Protein Alterations Associated with Human Colon Cancer Cancer Res., April 1, 2002; 62(8): 2437 - 2442. [Abstract] [Full Text] [PDF]

				J. D. McCaffery, M. Gapany, R. A. Faust, A. T. Davis, G. L. Adams, and K. Ahmed Nuclear Matrix Proteins as Malignant Markers in Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, March 1, 1997; 123(3): 283 - 288. [Abstract] [PDF]